Bank Of America Corp Savara Inc Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Savara Inc stock. As of the latest transaction made, Bank Of America Corp holds 283,242 shares of SVRA stock, worth $906,374. This represents 0.0% of its overall portfolio holdings.

Number of Shares

283,242

Previous 208,549 35.82%

Holding current value

$906,374

Previous $840,000 42.86%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.96 - $5.07 $295,784 - $378,693	74,693 Added 35.82%	283,242 $1.2 Million
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $143,925 - $209,990	39,324 Added 23.24%	208,549 $840,000
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $373,010 - $497,644	89,024 Added 111.0%	169,225 $842,000
Q4 2023 Feb 14, 2024	BUY	$3.18 - $4.9 $106,033 - $163,385	33,344 Added 71.16%	80,201 $376,000
Q2 2023 Aug 14, 2023	SELL	$1.69 - $3.24 $55,856 - $107,085	-33,051 Reduced 41.36%	46,857 $149,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.82 $126,716 - $223,338	79,198 Added 11154.65%	79,908 $155,000
Q4 2022 Feb 10, 2023	BUY	$1.11 - $1.64 $138 - $205	125 Added 21.37%	710 $1,000
Q3 2022 Nov 14, 2022	BUY	$1.36 - $1.88 $680 - $940	500 Added 588.24%	585 $1,000
Q1 2022 May 16, 2022	SELL	$1.05 - $1.36 $933 - $1,209	-889 Reduced 91.27%	85 $0
Q4 2021 Feb 08, 2022	SELL	$1.04 - $1.34 $21,914 - $28,236	-21,072 Reduced 95.58%	974 $1,000
Q3 2021 Nov 15, 2021	SELL	$1.18 - $1.64 $6,487 - $9,016	-5,498 Reduced 19.96%	22,046 $30,000
Q2 2021 Sep 13, 2021	BUY	$1.51 - $2.29 $41,591 - $63,075	27,544 New	27,544 $47,000

Others Institutions Holding SVRA

# of Institutions

128

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Savara Inc Transaction History